Tissue-specific enhancer active in prostate

C - Chemistry – Metallurgy – 12 – N

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C12N 15/86 (2006.01) A61K 31/70 (2006.01) A61K 38/00 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C12N 5/10 (2006.01) C12N 9/64 (2006.01) C12N 15/11 (2006.01) C12N 15/57 (2006.01) C12N 15/85 (2006.01) C12N 15/861 (2006.01) C12N 15/87 (2006.01)

Patent

CA 2181073

The invention provides a human prostate-specific transcriptional regulatory sequence, polylnucleotide comprising such regulatory regions, toxin gene constructs wherein a toxin gene is expressed under the transcriptional control of a human prostate-specific transcriptional regulatory sequence, and methods for treating prostate disease using such toxin gene constructs.

Cette invention concerne une séquence régulatoire transcriptionnelle humaine spécifique de la prostate, un polynucléotide comprenant lesdites régions régulatoires, des structures de gène de toxine dans lesquelles un gène de toxine est exprimé sous le contrôle transcriptionnel d'une séquence régulatoire transcriptionnelle humaine spécifique de la prostate, et des procédés de traitement des maladies de la prostate à l'aide de ces structures de gène de toxine.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Tissue-specific enhancer active in prostate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tissue-specific enhancer active in prostate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue-specific enhancer active in prostate will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-1753391

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.